jRCT2051210123已完成不适用
Phase I single and multiple ascending dose trial of NTa53, Confirmation of pharmacokinetics and safety of NTa53 in healthy Japanese adult males volunteer for single and repeated dose
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 62
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Other
- 盲法
- Double Blind
入排标准
- 年龄范围
- 20age old over 至 45age old under（—）
- 性别
- Male
入选标准
- •Healthy Japanese male of 20-45 years of age at the time of the informed consent
- •Judged by the investigator as being eligible at a result of the screening test
- •Other protocol-specified inclusion criteria may apply
排除标准
- •History of allergy symptoms such as asthma, atopic dermatitis, etc.
- •Judged by the investigator as being ineligible
- •Other protocol-specified exclusion criteria may apply
结局指标
主要结局
-
Pharmacokinetics and safety
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
A Phase 1 Single and Multiple Ascending Dose Study to Assess the Safety and Pharmacokinetics of SZN-043, a Novel Bispecific Fusion Protein Targeting ASGR1 and ZNRF3/RNF43, in Healthy Volunteers and Subjects with Liver CirrhosisAlcoholic HepatitisInflammatory and Immune System - Other inflammatory or immune system disordersLiver CirrhosisACTRN12622000392763Surrozen Operating, Inc.40
已完成
不适用
Evaluation of biomarkers for JAK inhibitorKCT0005706Seoul National University Hospital8
已完成
1 期
A Phase I Single-Ascending Dose and Multiple-Ascending Dose Study of RO6889450 in Healthy Japanese MaleHealthy adultsJPRN-jRCT2080224516Chugai Pharmaceutical Co., Ltd.64
已完成
1 期
PAT-SM6 in Patients with Recurrent In-Transit Cutaneous MelanomaRecurrent in-transit cutaneous melanomaCancer - Malignant melanomaSkin - Other skin conditionsACTRN12610000733077Patrys Limited9
尚未招募
1 期
SAD, Phase I Trial to Assess Safety, Tolerability and PK Profile of MSP008-22in Patients With Advanced Solid TumoursCTRI/2022/06/043504Godavari Biorefineries Limited